MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Levodopa(L-dopa)"

  • 2016 International Congress

    Impulsive-compulsive behaviors in patients with Parkinson’s disease and demographically-comparable group of healthy controls

    M.A. Nikitina, I.A. Zhukova, V.M. Alifirova, N.G. Zhukova, O.P. Izhboldina, J.S. Mironova, M.A. Titova, N.G. Brazovskaya, S.E. Sukhanov (Tomsk, Russia)

    Objective: To assess patients with Parkinson's disease (PwPD) impulsive-compulsive behaviors (ICBs) prevalence compared to healthy controls (HCs) group, to analyze PD clinical features, ICBs risk…
  • 2016 International Congress

    Dynamic prediction for multiple repeated measures and event time data: An application to Parkinson’s disease

    S. Luo, J. Wang (Houston, TX, USA)

    Objective: To develop methods for model-based personalized dynamic prediction of future outcome measure trajectories and risks of target events for the Parkinson's disease patients. Background:…
  • 2016 International Congress

    Hospitalisation following different initial therapies in early Parkinson’s disease: Analysis of hospital episodes statistics from the PD MED EARLY trial

    S. Muzerengi, R.L. Woolley, C. Rick, N. Ives, F. Dowling, R. Gray, C.E. Clarke, PD MED Collaborative Group (Birmingham, United Kingdom)

    Objective: To compare hospitalisation rates of Parkinson's disease (PD) patients randomised between three different classes of oral medications used for early PD treatment. Background: PD…
  • 2016 International Congress

    Conversion of patients from immediate release carbidopa-levodopa (IR CD-LD) and sustained release carbidopa-levodopa (SR CD-LD) to extended-release carbidopa-levodopa (ER CD-LD) in clinical practice

    S.J. LoRusso, B. Ouyang, B.R. Barton (Chicago, IL, USA)

    Objective: To evaluate the real-world response of patients who are converted from IR CD-LD and SR CD-LD to ER CD-LD in an academic practice. Background:…
  • 2016 International Congress

    Developing a new home monitoring device for dyskinesia in Parkinson’s disease

    J.E. Alty, J. Cosgrove, M.A. Lones, S. Jamieson, P. Duggan-Carter, C. Peacey, C. Wicks, R.F. Naylor, A.J. Turner, S.L. Smith (Leeds, United Kingdom)

    Objective: To evaluate how accurately a new device can discriminate different clinical severities of dyskinesia from non-dyskinetic movements in patients with Parkinson's disease (PD). Background:…
  • 2016 International Congress

    Real world conversion of levodopa to a novel extended release levodopa preparation: Determining predictors and dose ratios

    W. Ondo, P. Coss, M. Christie (Houston, TX, USA)

    Objective: To determine predictors of response and conversion ratios for a novel extended release levodopa preparation. Background: A new extended release levodopa preparation, Rytary®, has…
  • 2016 International Congress

    Levodopa-carbidopa intestinal gel via PEG-J for advanced Parkinson’s disease- A single centre experience

    E. Pekkonen, J. Lyytinen, O. Lindström, L. Kylänpää, M. Udd (Helsinki, Finland)

    Objective: To investigate clinical outcome and possible complications of LCIG in patients with advanced PD in years 2006-2014 at Helsinki University Hospital. Background: Continuous levodopa-carbidopa…
  • 2016 International Congress

    A randomized controlled clinical study to evaluate efficacy, safety and tolerability of SC L-dopa/carbidopa (ND0612H) infusion regimens in fluctuating PD patients

    K. Kieburtz, C.W. Olanow, Y. Cohen, S. Oren (Rochester, NY, USA)

    Objective: To evaluate the efficacy, safety & tolerability of continuous subcutaneous infusion regimens of ND0612H. Background: L-dopa remains the most effective PD medication, however oral…
  • 2016 International Congress

    Objective measures of Parkinsonian motor symptoms using a continuously worn smartwatch

    N. Fixler, L. Reitblat, A. Wagner, S. Cohen, M. Afek, P. Bonato, J.F. Daneault, N. Golabchi, S. Moore, A. Patel, C. Cho, L. Bataille (Petach Tikva, Israel)

    Objective: To determine whether smartwatch sensor data correlates with clinician-measured Parkinson's disease symptoms. Background: Data collected with smartwatches could be used for long-term, continuous assessment…
  • 2016 International Congress

    Automated Telehealth Diagnostics for Remote Parkinson Monitoring

    D.A. Heldman, D.A. Harris, T. Felong, B. Goldberg, J.P. Giuffrida, E.R. Dorsey, M.A. Burack (Cleveland, OH, USA)

    Objective: To clinically assess and evaluate the impact of automated telehealth diagnostics on patients with Parkinson's disease (PD). Background: A single evaluation in a clinical…
  • « Previous Page
  • 1
  • …
  • 56
  • 57
  • 58
  • 59
  • 60
  • …
  • 62
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley